<DOC>
	<DOCNO>NCT03078374</DOCNO>
	<brief_summary>The purpose study obtain single-center safety feasibility data patient manage reduced anti-coagulation , incidence thrombotic bleeding adverse event associate HeartMate 3 LVAS therapy .</brief_summary>
	<brief_title>MAGENTUM 1 HeartMate 3 LVAS : A Single Center Prospective Controlled Study ( MAGENTUM 1 )</brief_title>
	<detailed_description>Patients implant HeartMate 3 device bridge heparin target International Normalized Ratio ( INR ) 2,0 - 3,0 reach anticoagulation therapy Warfarin . Along Warfarin , Acetylsalicylic Acid ( ASA ) administer dose 100mg per day . Enrollment study take place 1-6 week post implant HeartMate 3 . Low-intensity anticoagulation protocol start 6 week implant . Target INR 1,5-1,9 maintain ASA administer dose 100mg per day adjustment base VerifyNow test . Follow last 6 month HeartMate 3 implantation . Subsequently , objective study analyze evaluate .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>patient implant HeartMate 3 LVAS irrespective indication data collection major thrombophilic mutation include antiphospholipid syndrome lupus anticoagulant test prior lowintensity protocol anticoagulation initiation perform patient compliant anticoagulation management judgment investigator patient stable condition anticipate home discharge absence inform consent presence additional MCS e.g . ECMO , RVAD le 7 day prior low intensity protocol anticoagulation initiation know history major thrombotic event e.g . DVT presence biological valve prosthesis aortic position leave atrial appendage patient atrial fibrillation flutter address resection exclusion time implant hemodynamically significant symptomatic carotid artery stenosis prior lowintensity protocol anticoagulation initiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Reduced anti-coagulation , mechanical circulatory support .</keyword>
</DOC>